Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2009 Oct;50(4):1113-20.
doi: 10.1002/hep.23133.

Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study

Affiliations
Multicenter Study

Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study

Christine Carter-Kent et al. Hepatology. 2009 Oct.

Abstract

Nonalcoholic fatty liver disease (NAFLD) may have distinct histological features in children and adults, but to date limited data are available on the spectrum and significance of histological lesions in pediatric patients. We conducted a multicenter study of children with well-characterized, biopsy-proven NAFLD to (1) assess the presence and significance of a constellation of histological lesions and (2) identify clinical and laboratory predictors of disease severity. One hundred thirty children with NAFLD seen from 1995 to 2007 in five centers in the United States and Canada were studied. Clinical and laboratory data were collected. Slides stained with hematoxylin-eosin and trichrome were evaluated by two liver pathologists. The NAFLD activity score (NAS) and the pattern of liver injury (type 1 or adult versus type 2 or pediatric nonalcoholic steatohepatitis [NASH]) were recorded. Fibrosis was staged using a published 7-point scale. The median age was 12 years (range, 4-18 years); 63% were boys, and 52% were Caucasian. Fibrosis was present in 87% of patients; of these, stage 3 (bridging fibrosis) was present in 20%. No patient had cirrhosis. The median NAS was 4. Overlapping features of both type 1 (adult pattern) and type 2 (pediatric pattern) NASH were found in 82% of patients. Compared with patients with no or mild fibrosis, those with significant fibrosis were more likely to have higher lobular and portal inflammation scores (P < 0.01), perisinusoidal fibrosis (P < 0.001), and NAS > or =5 (P < 0.005). Serum aspartate aminotransferase levels were the only clinical or laboratory data that independently predicted severity of fibrosis (P = 0.003).

Conclusion: Our results highlight the limitations of published proposals to classify pediatric NAFLD, and identified histological lesions associated with progressive disease.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Liver biopsy samples from pediatric patients with NAFLD. Liver biopsy specimens were formalin-fixed, paraffin-embedded, and stained with hematoxylin-eosin. The specimens shown are representative of the various histopathological features found in children with NAFLD. (A) Portal inflammation. (B) Lobular inflammation. (C) Bridging fibrosis. (Original magnification ×400.)
Fig. 2
Fig. 2
ROC depicting serum AST as a predictor of significant fibrosis in patients with NAFLD. AST does not appear to accurately predict the presence of fibrosis in these patients. Approximate area under the ROC curve = 0.63.

Similar articles

Cited by

References

    1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221–1231. - PubMed
    1. Wieckowska A, Feldstein AE. Nonalcoholic fatty liver disease in the pediatric population: a review. Curr Opin Pediatr. 2005;17:636–641. - PubMed
    1. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. HEPATOLOGY. 2004;40:1387–1395. - PubMed
    1. Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics. 2006;118:1388–1393. - PubMed
    1. Brunt EM. Pathology of fatty liver disease. Mod Pathol. 2007;20(Suppl 1):S40–S48. - PubMed

Publication types

Substances